Consensus guidelines for the design and implementation of clinical trials in ALS

[1]  R. Sufit,et al.  Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) , 1999, Neurology.

[2]  R. Barohn,et al.  Toward earlier diagnosis of amyotrophic lateral sclerosis , 1998, Neurology.

[3]  J. Cedarbaum,et al.  Prognostic indicators of survival in ALS , 1998, Neurology.

[4]  M. Gaweł,et al.  Effect of recombinant human insulin-like growth factor-I on progression of ALS , 1997, Neurology.

[5]  J. Petajan,et al.  Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis , 1997, Muscle & nerve.

[6]  K. Schulz.  The quest for unbiased research: Randomized clinical trials and the CONSORT reporting guidelines , 1997, Annals of neurology.

[7]  Michelle Mendoza,et al.  Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials , 1997, Journal of the Neurological Sciences.

[8]  G. Parry,et al.  Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis , 1996, Neurology.

[9]  National-Isometric-Muscle-Strength-Database-Consor.  Muscular weakness assessment: use of normal isometric strength data. The National Isometric Muscle Strength (NIMS) Database Consortium. , 1996, Archives of physical medicine and rehabilitation.

[10]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[11]  G. Parry,et al.  A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis , 1996 .

[12]  S H Appel,et al.  Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. , 1995, Brain : a journal of neurology.

[13]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[14]  J. R. Brinkmann,et al.  The natural history of amyotrophic lateral sclerosis , 1993, Neurology.

[15]  T. Munsat,et al.  Recombinant growth hormone treatment of amyotrophic lateral sclerosis , 1993, Muscle & nerve.

[16]  P. Andres,et al.  Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis , 1988, Neurology.

[17]  J. Caroscio,et al.  Amyotrophic lateral sclerosis. Its natural history. , 1987, Neurologic clinics.

[18]  W. Bradley,et al.  Amyotrophc Lateral Sclerosis: Part 1. Clinical Features, Pathology, and E h c d Issues in Management* , 2004 .

[19]  A. Chiò,et al.  Motor neuron disease in the province of Turin, Italy, 1966–1980 Survival analysis in an unselected population , 1984, Journal of the Neurological Sciences.

[20]  A D Rosen,et al.  Amyotrophic lateral sclerosis. Clinical features and prognosis. , 1978, Archives of neurology.

[21]  P. Preux,et al.  Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. , 1996, Neuroepidemiology.

[22]  I. Hemmi,et al.  Clinical Statistics in 515 Fatal Cases of Motor Neuron Disease , 1984 .

[23]  Olarte Mr.  Therapeutic trials in amyotrophic lateral sclerosis. , 1982 .